Close

Close

ESMO FAMILY SITES

ESMO » CAREER & GRANTS » YOUNG ONCOLOGISTS CORNER » JOURNAL CLUB

NEW! Young Oncologists’ Journal Club

ESMO Young Oncologists Committee proudly announce the launch of the YO Journal Club. Every 2-3 weeks a member of the YOC will provide you with an appraisal of an important clinical and/or translational article published in a major Journal together with their comments analysing the clinical relevance of the article and possible considerations.

Get involved by reading the review, share your thoughts and raise questions for discussion by logging in and commenting on the article. Commenting is reserved to ESMO Members only.

Latest issues

15 May 2012 - Intratumor heterogeneity: Does the strength of a tree lie in its trunk or in its branches?

Leticia De Mattos-Arruda, MD

Translational research

The concept that tumors are essentially heterogeneous and contain a range of subpopulations of cells with different metastatic potential is not new (Fidler et al. Cancer Res, 1978). Intratumor heterogeneity of target molecules is ...

1 comments - Last comment 15 hours ago

3 May 2012 - Patient selection for Oncology Phase I trials: a multi- institutional study of prognostic factors

Jesus Corral, MD

Treatment of cancer (surgery, radiotherapy, biologic therapy and anticancer agents)

Background

The appropriate selection of patients for early clinical trials presents a major challenge. Previous institutional studies focusing on this problem were limited by small size and by interpractice ...

No comments

12 Apr 2012 - Phase II study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients with Advanced Bone and Soft Tissue Sarcomas

Jörn Rüssel, MD

Sarcomas

Background

Soft tissue sarcomas (STS) and bone sarcomas are a heterogenous group of malignant tumors of mesenchymal cell origin. The annual incidence is around 2-3/100.000, thus accounts for approx. 1 % of solid ...

No comments

20 Mar 2012 - Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

Matthias Preusser, MD

Translational research

Activating mutations of the serine threonine kinase v-RAF murine sarcoma viral oncogene homologue B1 (BRAF), most commonly of the V600E type, are found in a wide range of human neoplasms. The small molecule inhibitors of BRAF ...

No comments

7 Mar 2012 - FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone as First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer

Tamer Refaat, MD PhD

Breast cancer

For decades, Tamoxifen has been the gold standard breast cancer hormonal therapy. In addition, various aromatase inhibitors (AIs) have been investigated in both the adjuvant and metastatic settings. Several randomized ...

3 comments - Last comment 2 months ago

29 Feb 2012 - Adjuvant therapy for completely resected gastric cancer with D2 LN Dissection

Konstantinos Kamposioras, MD

Gastrointestinal cancers

Gastric cancer is the second most common cause of cancer-related death worldwide. Even in potentially curative resections 50% to 90% of patients will die of locoregional or distant recurrence. Although randomized controlled trials ...

No comments

8 Feb 2012 - Nasopharyngeal carcinoma – a rare but potentially curable disease

Assist.Prof. Michalis V. Karamouzis MD PhD

Head and neck cancers

Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial, published in the Journal of the National Cancer Institute in November 2011 (Chen QY, et al.)

No comments

17 Jan 2012 - Bevacizumab in the Primary Treatment of Advanced Ovarian Cancer

Dr Susana Banerjee MA MRCP PhD

Gynecologic malignancies

The efficacy of bevacizumab in combination with chemotherapy in ovarian cancer as first-line treatment is addressed by two phase III trials which were published in the New England Journal of Medicine in December 2011.

No comments

9 Jan 2012 - Overcoming endocrine resistance in advanced breast cancer by inhibiting the mTOR pathway

Valentina Guarneri, MD, PhD

Breast cancer

Hormone receptor positive tumors are largely dependent on hormones and endocrine manipulation is the cornerstone of therapy. However, several hormone receptor positive patients are not responsive to hormonal therapy. Moreover, ...

2 comments - Last comment 4 months ago

19 Dec 2011 - Prospective molecular marker analyses of EGFR and KRAS from a randomized placebo controlled study of erlotinib maintenance therapy in advanced Non-Small-Cell-Lung Cancer

Marina Chiara Garassino MD;Sheila Piva MD

Translational research

Over the past few years, the development of antitumoral molecular targeted strategies has replaced the more empiric screening method of researching new cytotoxic drugs. The understanding of molecular mechanisms which underlie ...

No comments

30 Nov 2011 - ASCO Practice guideline on antiemesis, update Nov. 2011

Karin Jordan, MD

Treatment of cancer (surgery, radiotherapy, biologic therapy and anticancer agents)
Complications of treatment and supportive measures

Clinicians should be aware that chemotherapy induced nausea and vomiting (CINV) are still one of the most feared side effects of chemotherapy. With correct use of antiemetics, CINV can be prevented in almost 70% up to 80% of ...

No comments

16 Nov 2011 - Chemotherapy and Vascular Disrupting Agents in advanced NSCLC: still looking for an ATTRACT-1ve partner

Dr Raffaele Califano MD

Lung cancer and other chest malignancies

As clinicians, we all strive to improve outcomes for our patients and we are always disappointed when a large phase III trial evaluating a novel agent reports negative results. As in life, we all learn from mistakes and cancer ...

1 comments - Last comment 6 months ago

4 Nov 2011 - Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma

Matthias Preusser, MD

Central nervous system malignancies

The monoclonal anti-vascular endothelial growth factor (VEGF) antibody bevacizumab has recently received considerable attention from neuro-oncologists. Bevacizumab has demonstrated high radiographic response rates, a decreased ...

1 comments - Last comment 6 months ago

11 Oct 2011 - Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in pretreated NSCLC patients: have we found a KRAS targeting agent?

Giulio Metro, MD

Lung cancer and other chest malignancies

Recent advances in the understanding of the molecular aberrations that underlie and sustain the oncogenic process of non-small cell lung cancer (NSCLC) have progressively diversified treatment approach to this disease. However, if ...

1 comments - Last comment 6 months ago

5 Oct 2011 - Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants

David Olmos, MD

Genitourinary cancers

Over 900,000 new cases of prostate cancer are diagnosed worldwide each year. Prostate cancer is the second commonest cause of male cancer-related death in the United States and the sixth worldwide with more than 250,000 deaths ...

2 comments - Last comment 7 months ago

21 Sep 2011 - Maintenance therapy with rituximab prolongs the progression free survival in follicular lymphoma. Results from the PRIMA trial.

Sari Riihijarvi, MD

Hematologic malignancies

Follicular lymphoma (FL) is the most common indolent lymphoma in the Western countries. It is considered rarely curable with conventional chemotherapy due to its tendency to relapse. FL maintains sensitivity to different ...

No comments

12 Sep 2011 - Adjuvant chemotharpy for stage II colon cancer with poor prognostic features: the controversy is still open

Erika Martinelli MD

Colorectal cancer

Colorectal cancer (CRC) is the third most common cancer worldwide and surgery is the cornerstone treatment in locoregional disease (stage I, II and III). The aim of adjuvant therapy is to eradicate residual micrometastasis thus ...

2 comments - Last comment 5 months ago

16 Aug 2011 - A step forward in pancreatic ductal adenocarcinoma gene expression classification: Subtypes linked to survival and drug sensibility

Alessandro Leal MD

Gastrointestinal cancers

Pancreatic ductal adenocarcinoma (PDA) has been a challenging disease, since many randomized controlled trials have failed to demonstrate improved survival with several agents considered effective for other malignancies. In ...

3 comments - Last comment 9 months ago

29 Jul 2011 - Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC)

Dr Susana Banerjee MA MRCP PhD

Gynecologic malignancies

PARP inhibitors: Beyond hereditary ovarian cancer?

Poly(ADP-ribose)polymerase (PARP) inhibitors are showing considerable promise for the treatment of BRCA mutation-associated ovarian and breast cancer. This ...

3 comments - Last comment 9 months ago

19 Jul 2011 - Gene expression profiling predicts the development of oral cancer

Gilberto de Castro Junior MD PhD

Head and neck cancers

Oral squamous cell carcinoma remains as the most prevalent head and neck cancer worldwide, with higher incidence rates in developing countries, as a consequence of a more elevated exposure to tobacco and alcohol carcinogens.

3 comments - Last comment 10 months ago

6 Jul 2011 - New treatment in prostate cancer: Abiraterone and the beginning of a new era in prostate cancer

Christophe Massard MD

Genitourinary cancers

Prostate cancer is the most common cancer, and the second leading cause of death from cancer, in males in most Western countries. Prostate cancer has an exquisite sensitivity to androgen deprivation therapy, although the disease ...

No comments

17 Jun 2011 - Combined EGFR / MET targeting in lung cancer therapeutics – the transition from preclinical evidence to clinical data

Michalis V. Karamouzis MD, PhD

Lung cancer and other chest malignancies

Spigel D.R., et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 2011 (suppl; abstr 7505)

The hepatocyte ...

No comments

7 Jun 2011 - BRAF selective inhibitors in advanced melanoma. The revolution has begun.

Dr Raffaele Califano, MD

Melanoma and skin cancers

These are exciting times for clinicians treating patient with Malignant Melanoma. Metastatic melanoma carries a poor prognosis and despite the tremendous efforts in cancer research the results have been disappointing.
Things ...

1 comments - Last comment 11 months ago

31 May 2011 - Cost-effectiveness of bevacizumab in the management of ovarian cancer: too high the costs, or too low the benefits?

Valentina Guarneri, MD, PhD

Gynecologic malignancies

Ovarian cancer is the second most common gynaecological malignancy, and is the leading cause of gynecologic cancer-related death in Europe and US. The majority of the cases are diagnosed in advanced stage, with limited chance of ...

3 comments - Last comment 12 months ago

16 May 2011 - Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial.

Alessandro Leal, MD;Evandro de Azambuja, MD, PhD

Breast cancer

In the past, early stage breast cancer patients have been surgically treated with radical mastectomy and axillary lymph node dissection (ALND), based on the premise that wider resections optimize the chances of cure and provide ...

2 comments - Last comment 1 year ago

2 May 2011 - KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

Konstantinos Kamposioras, MD

Colorectal cancer

Treating metastatic colorectal cancer (mCRC) is becoming increasingly challenging especially after the development of new therapeutic agents targeting Epidermal Growth Factor Receptor (EGFR) and angiogenesis. Cetuximab and ...

2 comments - Last comment 11 months ago

BACK TO TOP

BACK TO TOP

PRINT THIS PAGE

PRINT THIS PAGE